Multi-Scale Investigations of Respiratory Mucus/Mucin Structure and Function in Health and Disease
健康和疾病中呼吸道粘液/粘蛋白结构和功能的多尺度研究
基本信息
- 批准号:10684185
- 负责人:
- 金额:$ 275.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-15 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAirAsthmaBindingBiochemicalBiochemistryBiologicalBiologyBiophysicsBiostatistics CoreBronchiectasisCactaceaeCharacteristicsChronicChronic Obstructive Pulmonary DiseaseChronic lung diseaseCiliaCiliary Motility DisordersClawCommunicable DiseasesComplementCystic FibrosisDNADevelopmentDiseaseDistalDoctor of PhilosophyElectronsElectrostaticsElementsEnsureFailureFunctional disorderGelGenesGenetic studyGeometryGlandGoalsHealthHost DefenseHumanHydration statusHydrophobicityImageIn VitroInfectious AgentInhalationInvestigationKnowledgeLeftLengthLungLung diseasesMeasurementMembraneMicroscopicMolecularMolecular BiologyMorphologyMucinsMucolyticsMucous body substanceMusNatureObstructionOutcomePathogenesisPatientsPolymersPopulationPower strokePredispositionPropertyPublic HealthPumpQuality ControlReagentRecording of previous eventsRegulationResearchResearch PersonnelRespiratory DiseaseRespiratory MucinRiskRoleSeriesSkinSlideStretchingStructureSubmucosaSurfaceSystemTandem Repeat SequencesTestingTherapeuticTherapeutic AgentsToxic Environmental SubstancesToxinWaterWorkairway surface liquidaqueousbiophysical propertiescombatcrosslinkdimereffective therapyfluid flowgenetic approachimprovedin vivolung healthmucus clearancemucus-associated lung diseasesneutrophilnovelnovel therapeuticsrare genetic disorderrespiratorytherapy developmenttransmission processtreatment strategyviscoelasticity
项目摘要
OVERALL ABSTRACT
The mucus clearance system constitutes the primary airway host defense system against inhaled infectious
agents and toxins. However, despite more than two centuries of research into the nature of the mucus clearance
system, surprising gaps in our knowledge of fundamental aspects of this system persist. Filling in these gaps is
important for improving public health strategies to combat respiratory infectious diseases. Filling in these gaps
is also important for elucidating the pathogenesis of and developing therapies for chronic pulmonary diseases,
including COPD, asthma, NCFB, and rare genetic diseases (CF, PCD), which are by definition characterized by
mucus accumulation in the lung. This PPG proposes to investigate fundamental, but poorly understood, aspects
of the mucus clearance system that must be quantitated to understand mucus function in health and dysfunction
in disease. Each PPG project has two specific aims focused on basic mucin function and one focused on
translational aspects of mucin pathobiology. Project 1 (“Mucin Structure and Associations in Respiratory Mucus”,
Michael Rubinstein, PhD, PI) will investigate fundamental aspects of the organization of mucins in solution and
within the mucus layer. These studies will be complemented by studies of the addition of “abnormal polymers”,
e.g., DNA, to mucus solutions. Project 2 (“Why are mucins so gigantic and is it safe/effective to sever them
therapeutically?”, Richard C. Boucher, MD, PI) will focus on the fundamental question as to why human airway
mucin polymers are of such enormous size (300 MDa, Rg 250 nm) and characterize the ratio of efficacy (chain
length reduction) vs risk (off-target chain unwinding) required for the development of mucolytics for lung disease.
Project 3 (“Membrane-bound mucins on the airway surface ensure efficient mucus clearance and lung health”,
Brian Button, PhD, PI) will study the relationships between cilia, PCL, and the mucus layer required for transport,
focusing on a novel hydraulic “pushing” vs classic “clawing” mechanisms. In addition, barrier functions of PCL
and regulation thereof will be studied. Project 4 (“Biophysical and structural characterization of airway
submucosal gland mucus in health and cystic fibrosis”, Ronit Freeman, PhD, PI) will focus on a novel attribute
of submucosal gland (SMG) mucus, a strand/bundle insoluble component, and how strands/bundles contribute
to SMG mucus function in health and disease. Three cores support the PPG: 1) Core A, the
Administrative/Biostatistical Core, Multi-PIs Richard C. Boucher, MD, and Michael Rubinstein, PhD, supplies
project management and statistical support for the PPG; 2) Core B, the Mucus/Mucin Analytics Core, PI Mehmet
Kesimer, PhD, provides quality control of all mucin reagents for the PPG and novel biochemical/biophysical
measurements; and 3) Core C, the Imaging Core, PI Camille Ehre, PhD, provides electron microscopic,
molecular, and morphologic analyses to the projects. The overall goals of the PPG are to elucidate the structure
and function of mucus in health, how these characteristics are degraded in disease, and identify strategies for
development of novel therapeutic agents to treat muco-obstructive diseases.
总体摘要
粘液清除系统是机体抵抗吸入性感染的主要防御系统
代理和毒素。然而,尽管两个多世纪的研究,粘液清除的性质,
然而,我们对这一体系的基本方面的认识仍然存在令人惊讶的差距。填补这些空白的是
这对改善防治呼吸道传染病的公共卫生战略十分重要。填补这些空白
对于阐明慢性肺疾病的发病机理和开发慢性肺疾病的治疗也是重要的,
包括COPD、哮喘、NCFB和罕见遗传病(CF、PCD),根据定义,其特征在于
肺内粘液积聚。这个PPG建议调查基本的,但知之甚少的方面,
粘液清除系统,必须量化,以了解粘液功能在健康和功能障碍
疾病。每个PPG项目都有两个具体目标,一个侧重于基本粘蛋白功能,另一个侧重于
粘蛋白病理生物学的翻译方面。项目1(“呼吸道粘液中的粘蛋白结构和关联”,
Michael Rubinstein博士,PI)将研究溶液中粘蛋白组织的基本方面,
在粘液层中。这些研究将通过添加“异常聚合物”的研究加以补充,
例如,在一个实施例中,从DNA到粘液溶液。项目2(“为什么粘蛋白如此巨大,切断它们是否安全/有效
治疗?",Richard C. Boucher,MD,PI)将重点讨论为什么人体气道
粘蛋白聚合物具有如此巨大的尺寸(300 MDa,Rg 250 nm),并且表征了功效比(链
长度减少)与风险(脱靶链解旋)之间的关系。
项目3(“气道表面的膜结合粘蛋白确保有效的粘液清除和肺部健康”,
布赖恩按钮,博士,PI)将研究纤毛,PCL和运输所需的粘液层之间的关系,
集中在一个新的液压“推”与经典的“抓”机制。此外,PCL的屏障功能
并对其进行研究。项目4(“呼吸道的生物物理和结构特征
健康和囊性纤维化中的粘膜下腺体粘液”,Ronit Freeman,PhD,PI)将关注一种新的属性
粘膜下腺(SMG)粘液,一种链/束不溶性组分,以及链/束如何贡献
SMG粘液功能在健康和疾病。三个核心支持PPG:1)核心A,
管理/生物统计核心,多PI Richard C.鲍彻,医学博士和迈克尔鲁宾斯坦,博士,用品
PPG的项目管理和统计支持; 2)核心B,粘液/粘蛋白分析核心,PI Mehmet
Kesimer博士为PPG和新型生物化学/生物物理学提供所有粘蛋白试剂的质量控制
3)核心C,成像核心,PI Camille Ehre,PhD,提供电子显微镜,
分子和形态分析的项目。PPG的总体目标是阐明结构
粘液在健康中的作用,这些特征如何在疾病中降解,并确定
开发治疗粘膜阻塞性疾病的新型治疗剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard Charles Boucher其他文献
Richard Charles Boucher的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard Charles Boucher', 18)}}的其他基金
UNC Research Training Program in Respiratory Diseases and Critical Care
北卡罗来纳大学呼吸系统疾病和重症监护研究培训计划
- 批准号:
10714527 - 财政年份:2023
- 资助金额:
$ 275.76万 - 项目类别:
The molecular and cellular mechanisms of the STAT3 mutation-mediated pulmonary disorder in Autosomal Dominant Hyper IgE Syndrome (AD-HIES)
常染色体显性高 IgE 综合征 (AD-HIES) STAT3 突变介导的肺部疾病的分子和细胞机制
- 批准号:
10393987 - 财政年份:2022
- 资助金额:
$ 275.76万 - 项目类别:
Project 2: Why are mucins so gigantic and is it safe/effective to sever them therapeutically?
项目 2:为什么粘蛋白如此巨大?在治疗上切断它们是否安全/有效?
- 批准号:
10684198 - 财政年份:2022
- 资助金额:
$ 275.76万 - 项目类别:
The molecular and cellular mechanisms of the STAT3 mutation-mediated pulmonary disorder in Autosomal Dominant Hyper IgE Syndrome (AD-HIES)
常染色体显性高 IgE 综合征 (AD-HIES) STAT3 突变介导的肺部疾病的分子和细胞机制
- 批准号:
10584596 - 财政年份:2022
- 资助金额:
$ 275.76万 - 项目类别:
Diversity Supplement for PhD student Shamarie King under Multi-Scale Investigations of Respiratory Mucus/Mucin Structure and Function in Health and Disease
博士生 Shamarie King 在健康和疾病中呼吸道粘液/粘蛋白结构和功能的多尺度研究中的多样性补充
- 批准号:
10852415 - 财政年份:2022
- 资助金额:
$ 275.76万 - 项目类别:
Mucin sialylation drives epithelial cell senescence and severe asthma
粘蛋白唾液酸化导致上皮细胞衰老和严重哮喘
- 批准号:
10206266 - 财政年份:2020
- 资助金额:
$ 275.76万 - 项目类别:
Mucin sialylation drives epithelial cell senescence and severe asthma
粘蛋白唾液酸化导致上皮细胞衰老和严重哮喘
- 批准号:
10664889 - 财政年份:2020
- 资助金额:
$ 275.76万 - 项目类别:
Mucin sialylation drives epithelial cell senescence and severe asthma
粘蛋白唾液酸化导致上皮细胞衰老和严重哮喘
- 批准号:
10026633 - 财政年份:2020
- 资助金额:
$ 275.76万 - 项目类别:
Mucin sialylation drives epithelial cell senescence and severe asthma
粘蛋白唾液酸化导致上皮细胞衰老和严重哮喘
- 批准号:
10434719 - 财政年份:2020
- 资助金额:
$ 275.76万 - 项目类别:
相似国自然基金
湍流和化学交互作用对H2-Air-H2O微混燃烧中NO生成的影响研究
- 批准号:51976048
- 批准年份:2019
- 资助金额:61.0 万元
- 项目类别:面上项目
相似海外基金
Air pollution and Asthma in Canada: Projections of burden and the value of climate adaptation strategies
加拿大的空气污染和哮喘:负担预测和气候适应战略的价值
- 批准号:
485322 - 财政年份:2023
- 资助金额:
$ 275.76万 - 项目类别:
Operating Grants
Urban planning, siting of air pollution sources, and asthma disparities
城市规划、空气污染源选址和哮喘差异
- 批准号:
10567693 - 财政年份:2023
- 资助金额:
$ 275.76万 - 项目类别:
Evaluation of radon progeny and air pollution effects in asthma
评估氡子体和空气污染对哮喘的影响
- 批准号:
10723709 - 财政年份:2023
- 资助金额:
$ 275.76万 - 项目类别:
Action towards health equity and improved air quality in the Duwamish Valley: A multilevel asthma intervention
杜瓦米什山谷的健康公平和空气质量改善行动:多层次哮喘干预
- 批准号:
10562132 - 财政年份:2023
- 资助金额:
$ 275.76万 - 项目类别:
Investigating the interactions of air pollution and an anti-inflammatory asthma medication using scRNA sequencing
使用 scRNA 测序研究空气污染和抗炎哮喘药物的相互作用
- 批准号:
485433 - 财政年份:2023
- 资助金额:
$ 275.76万 - 项目类别:
Salary Programs
Molecular Mechanisms for Resolving Air Pollution Induced Pulmonary Inflammation: Potential Differences by Asthma and Sex (RAPIDAS)
解决空气污染引起的肺部炎症的分子机制:哮喘和性别的潜在差异(RAPIDAS)
- 批准号:
10718525 - 财政年份:2023
- 资助金额:
$ 275.76万 - 项目类别:
There's something in the air: disentangling the role of airborne microbes and pollutants in the inflammatory response of asthma along a latitudinal gradient in Canada
空气中弥漫着某种东西:沿着加拿大的纬度梯度,理清空气中的微生物和污染物在哮喘炎症反应中的作用
- 批准号:
571457-2021 - 财政年份:2022
- 资助金额:
$ 275.76万 - 项目类别:
Alliance Grants
Puerto Rico Asthma Integrated Response Program (PR-AIR)
波多黎各哮喘综合应对计划 (PR-AIR)
- 批准号:
10705253 - 财政年份:2022
- 资助金额:
$ 275.76万 - 项目类别:
Puerto Rico Asthma Integrated Response Program (PR-AIR)
波多黎各哮喘综合应对计划 (PR-AIR)
- 批准号:
10534086 - 财政年份:2022
- 资助金额:
$ 275.76万 - 项目类别:
Contextualizing Asthma Self-Management with Measures of Indoor Air Quality for Black Adults with Uncontrolled Asthma
将哮喘自我管理与哮喘不受控制的黑人成人的室内空气质量测量结合起来
- 批准号:
10671775 - 财政年份:2022
- 资助金额:
$ 275.76万 - 项目类别: